TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
CDXS

Codexis Inc

Healthcare · Biotechnology

1.30$ -3.6% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Codexis Inc (CDXS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 120 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CDXS
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
39 36 31 50 44 54 45 76 79 78 101 147 146 149 149 142 138 222 212 212 228 246 235 235 235 250 218 207 154 137 150 132 148 149 129 138 124 148 129 120
30 27 22 40 35 45 36 66 68 67 64 110 110 114 115 106 103 184 174 172 174 162 145 145 146 163 130 120 103 93 108 91 113 99 78 89 76 97 80 72
15 19 14 29 24 31 24 54 54 53 47 93 92 90 87 76 72 149 140 130 119 117 94 90 109 114 103 92 75 65 58 19 37 19 18 27 26 51 37 27
15 19 14 29 24 31 24 54 54 53 47 93 92 90 87 76 72 150 141 131 119 117 94 90 109 114 103 92 75 65 86 73 90 73 60 66 59 78 66 55
12 5.9 5.4 7.8 7.9 12 9.0 10 11 13 15 14 16 20 23 26 27 29 28 36 48 38 44 49 30 41 20 22 19 20 14 12 17 19 12 16 9.7 11 8.0 7.4
1.1 0.8 1.1 0.8 0.8 1.0 1.2 1.0 0.8 0.6 0.6 0.7 0.4 0.4 0.7 0.7 0.7 1.0 1.0 1.1 1.1 1.2 1.6 1.7 1.6 2.0 2.0 2.1 2.3 2.7 2.4 2.2 2.1 1.8 1.8 1.9 1.9 1.8 2.0 1.6
2.3 2.2 2.8 3.0 2.8 2.8 2.6 3.9 4.5 4.8 4.5 5.3 6.2 6.3 6.6 6.8 7.3 9.7 10 31 16 65 23 24 23 62 24 23 29 – – – – – – – – – – –
3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
0.3 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
16 17 19 19 22 29 29 23 24 22 50 48 44 44 50 47 47 52 48 50 58 82 77 76 81 106 92 83 63 50 70 71 75 82 79 83 85 97 86 87
12 12 14 13 17 25 22 16 18 17 19 17 15 15 22 19 20 25 23 24 33 33 29 30 32 49 38 36 38 36 29 31 35 24 21 15 18 25 15 24
– 0.4 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4 1.3 0.9 1.0 1.2 1.8 2.5 2.6 2.6 2.6 2.7 2.8 4.1 4.9 5.1 5.2 5.4 5.5 5.6 6.8 3.8 3.9 4.0 4.1 2.8 2.9 3.0 3.1 2.9 3.3 10
2.1 4.2 3.5 3.6 4.5 3.5 2.6 3.1 2.3 3.1 2.2 2.2 1.7 2.6 2.4 2.6 2.5 3.0 3.6 3.2 3.3 3.0 1.9 2.0 2.6 3.2 4.5 4.0 3.1 5.9 3.5 3.7 4.2 2.8 6.0 1.5 2.4 1.6 2.1 2.6
0.0 0.0 0.3 0.4 0.4 0.3 0.2 0.2 0.1 – 26 – – – – – – – – – – – – – – – – – – – 28 28 29 29 29 39 40 40 40 34
23 19 12 31 22 25 15 53 55 56 51 99 103 106 99 95 91 170 164 163 169 164 159 159 154 145 126 124 92 87 79 61 73 67 50 56 39 51 43 33
-287 -292 -300 -306 -316 -315 -324 -328 -330 -330 -336 -342 -342 -342 -350 -356 -362 -366 -375 -380 -378 -388 -396 -399 -409 -421 -444 -455 -490 -498 -509 -532 -552 -563 -583 -597 -616 -607 -615 -627
42 41 41 47 48 51 48 53 54 54 54 55 61 59 59 59 59 60 64 64 68 65 65 65 65 66 66 68 69 70 70 70 72 81 82 85 90 91 91 91

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?